No Data
No Data
This Is What Whales Are Betting On Novo Nordisk
Tandem Diabetes Insulin Pump Demand to Surge Despite Popular Demand Of Weight Loss Drugs, Bullish Analyst Says
Eli Lilly Commits $4.5B To New Facility, Banking On Mounjaro, Zepbound's Weight Loss Success Despite Short-Term Stock Challenges
BofA Securities Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating
Novo Nordisk Is Still a Buy, Analysts Say. Slowing Growth for Ozempic and Wegovy Isn't a Problem. -- Barrons.com
Eli Lilly Invests $4.5B In New Medicine Foundry for Advanced Drug Manufacturing To Push US Pharma Boundaries
loading...
70205719 : time to step in now, I think.
股勇者 OP : yes... the chart agrees with U
70205719 70205719 : wrong, if break 115, go to 111? or 105?